<DOC>
	<DOCNO>NCT01010542</DOCNO>
	<brief_summary>The purpose research study evaluate safety tolerability ILV-095 give individual moderate severe chronic plaque psoriasis . Another purpose study observe drug enters blood tissue time , body break drug whether body develop immune reaction ( sensitivity ) drug .</brief_summary>
	<brief_title>Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects</brief_title>
	<detailed_description>B1991002 study phase 1 adaptive design study terminate 14Mar2011 . Regular analyzes psoriasis assessment conduct per statistical plan indicate even every patient enrol rest study respond ( 23 additional subject ) , study meet primary efficacy endpoint . Pfizer Inc. terminate trial clinical team ask clinical investigator continue collect safety , pharmacokinetics pharmacodynamics data last subject last visit subject receive test article . Last Subject Last Visit occur 20May2011 .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Sexually active men woman must agree use medically acceptable form contraception study continue 16 week investigational product administration . Negative urine pregnancy test result woman . Body mass index ( BMI ) &gt; =18 kg/m2 body weight &gt; =50 kg . BMI calculate take subject 's weight , kilogram , divide square subject 's height , meter , screening : BMI = weight ( kg ) / ( height [ ] ) . Must meet follow criterion disease activity , screen and/or study entry ( subject washout prior therapy may meet level disease activity screen must enter study ) . Must stable moderate severe chronic plaque psoriasis cover &gt; =15 % body surface area candidate systemic therapy phototherapy . Psoriasis Area Severity Index ( PASI ) score &gt; 11 . Physician Global Assessment ( PGA ) psoriasis score &gt; =3 . Target lesion score &gt; =6 base physician rating select site erythema , plaque elevation scaling , minimum 2 plaque elevation score . A12point score use 14 scale domain . Target lesion scalp , axilla , face , groin . Presence history disorder may prevent successful completion study . Evidence unstable clinically significant disease ( eg , unstable cardiovascular , renal , respiratory , psychiatric disease serious disorder currently require physician care ) . Acute disease state ( eg , nausea , vomit , fever , diarrhea ) within 7 day study day 1 . Evidence skin condition ( eg , eczema ) psoriasis would interfere evaluation effect study medication psoriasis . Presence guttate , erythrodermic , pustular psoriasis . Active severe infection within 4 week study day 1 . Systemic malignancy within past 5 year include melanoma . Treated skin cancer ( basal cell carcinoma squamous cell carcinoma ) exclude . Evidence latent tuberculosis purify protein derivative ( PPD ) screening . PPD screening perform accord local standard use tuberculin skin test ( TST ) . Any result &gt; 5mm consider positive . Prior Bacillus CalmetteGuerin ( BCG ) take account interpret TST result . TST must perform screening period unless one performed within previous 3 month result available .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Single dose psoriasis study</keyword>
</DOC>